Partnership is core to our business model. We are committed to partnering with R&D based global pharma and biotech companies to bring innovative medicines to patients. With our highly recognized clinical development team and strong track record of successful new drug filings in China and other countries, we are uniquely positioned as a clinical development partner in China for global drug approval. We have successfully licensed the global rights of several assets from Jiangsu Hengrui Medicine, a top Chinese pharmaceutical company, and quickly brought them into global phase 2 trials.
We continue to actively seek new in-licensing and co-development opportunities. At present, the company focuses on the global and/or greater China rights of drugs for autoimmune diseases and other unmet medical need areas. We welcome opportunities for partnership around the globe. Please contact us at: BD@reistonebio.com.